News

Filter

1 to 9 of 76 results

India’s Cipla calls for revocation of Novartis’ Onbrez patents

01-11-2014

Indian drugmaker Cipla has asked the government to revoke five patents that Swiss pharma major Novartis…

CiplaIndiaMarkets & MarketingNovartisOnbrezPatentsPharmaceuticalRespiratory and PulmonaryUnibrez

New Zealand's PHARMAC funds four new medicines as part of major agreement with Novartis

New Zealand's PHARMAC funds four new medicines as part of major agreement with Novartis

20-10-2014

New Zealand's Pharmaceutical Managment Agency PHARMAC has agreed to fund four new medicines for which…

Antibiotics and Infectious diseasesCardio-vascularglycopyrroniumindacaterolNew ZealandNovartisOmalizumabPharmaceuticalRegulationRespiratory and PulmonaryTobramycin

Pfizer to commercialize Novartis partner Vectura's respiratory drugs in the UK

Pfizer to commercialize Novartis partner Vectura's respiratory drugs in the UK

04-09-2014

Swiss drug major Novartis has enlisted US pharma giant Pfizer to commercialize two respiratory products…

Chronic obstructive pulmonary diseaseMarkets & MarketingNovartisNovartis PharmaceuticalsPfizerPharmaceuticalRespiratory and PulmonarySeebri BreezhalerUKUltibro BreezhalerVectura

United Thera scores over Sandoz in Remodulin patent case

United Thera scores over Sandoz in Remodulin patent case

31-08-2014

US biotech company United Therapeutics’ shares leapt 28.5% to $117.83 on Friday, after the company…

GenericsLegalNovartisPatentsRemodulinRespiratory and PulmonarySandozUnited TherapeuticsUSA

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

21-08-2014

The asthma market in Brazil and Mexico currently faces severe coverage restrictions and, as the treatment…

Boehringer IngelheimBrazilGenentechMexicoNovartisPfizerPharmaceuticalRespiratory and PulmonarySpirivaXolair

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

30-04-2014

Swiss drug major Novartis today announced positive first results from the Phase III head-to-head LANTERN…

COPDEuropeHealth Medical PharmaMedicineNovartisPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretideUltibro Breezhaler

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

28-04-2014

Swiss drug major Novartis has announced encouraging top-line results from its Phase IV INSTEAD switch…

EuropeHealth Medical PharmaMedicineModerate COPDNovartisOnbrezPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretide

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

19-02-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

GermanyNorthern EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryUltibro BreezhalerXoterna Breezhaler

1 to 9 of 76 results

COMPANY SPOTLIGHT

Menarini

Back to top